Karl Beutner, DermBiont CEO
October 25, 2023 06:51 AM EDT
Financing

DermBiont rais­es $35.2M Se­ries B to ad­vance two der­ma­to­log­i­cal drugs through PhII

Katherine Lewin

News Reporter

Boston biotech DermBiont closed a $35.2 mil­lion fund­ing round Tues­day to ad­vance de­vel­op­ment of two of its der­ma­to­log­i­cal top­i­cal can­di­dates. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times